MTNB Overview

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.

Wall Street analysts forecast MTNB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MTNB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Matinas BioPharma Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased

Matinas BioPharma Holdings Inc. EPS for the last quarter amounts to -0.30 USD, decreased -9.09

Matinas BioPharma Holdings Inc (MTNB) has 2 emplpoyees as of July 01 2026.

Today MTNB has the market capitalization of 4.25M USD.